Medivation Rejects Sanofi’s $9 Billion Bid

The board of US biopharmaceuticals producer Medivation has unanimously rejected French drugmaker Sanofi’s $9.3 billion bid to acquire the company. David Hung, founder, president and CEO of the California-based prostate cancer specialist, said the cash offer, which he termed “opportunistically timed” as the company’s share price has deteriorated over the past several months, “substantially undervalues” the company.

Sanofi had offered to pay $52.50 a share in cash, which it said represented a 50% premium over Medivation’s two-month volume-weighted average. Despite the rejection, the French company indicated it is not prepared to abandon the hoped-for deal.

While Medivation “has chosen not to enter into discussions regarding this value-creating transaction,” Sanofi said it remains committed to the “compelling combination” and added that it is looking forward to “engaging directly with Medivation shareholders.” Sanofi said it is “a disciplined acquirer” and has a strong acquisition track-record.               

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.